Background Recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCNH)
is still a difficult-to-treat disease with poor clinical outcomes and limited treatment choices. In …

Background The aims of this study are to evaluate the efficacy and safety of first-line
treatment with chemotherapy plus cetuximab in real-world patients with recurrent or …

Background/Aim: Head and neck cancers account for 8% of all cancer cases worldwide.
However, identifying the optimal treatment for recurrent or metastatic head and neck cancer …

Background In patients with recurrent or metastatic head and neck squamous cell carcinoma
(R/M HNSCC) the estimated prognosis is usually poor. Patient-specific factors that affect …

Aim: Cetuximab was approved in 2008 for treating recurrent/metastatic (R/M) head-and-neck
squamous-cell carcinoma (HNSCC), and this study assessed the utilization of cetuximab for …

Background Cetuximab plus platinum‐based therapy (PBT) followed by cetuximab
maintenance until progression (EXTREME) is a guideline‐recommended first‐line treatment …

Background We report our experience with Indian patients who received palliative
chemotherapy with/without cetuximab for recurrent/metastatic squamous cell carcinoma of …

Background: The EXTREME regimen (cetuximab+ PBT≤ 6 cycles followed by cetuximab-
alone maintenance until progressive disease [PD]) was the first treatment in 30 years to …

Background The use of cetuximab in combination with platinum (P) plus 5-fluorouracil (F)
has previously been demonstrated to be effective in the treatment of metastatic squamous …

Simple Summary As the treatment advances, there were several novel agents developed for
R/M HNSCC, including an anti-epidermal growth factor receptor antibody, cetuximab, and …